Dermatologic Therapy With Immunosuppressive Agents

REFERENCES

• Moschella SA: Indications for and complications of chemotherapy in office dermatology. Presented before the American Academy of Dermatology, Chicago, 1974
   Google Scholar
• Farber EM, McClintock RP Jr: A current review of psoriasis. Calif Med 108:440–457, 1968
   PubMedGoogle Scholar
• Van der Korst JK: Psoriasis and arthritis: A review of recent literature. Folia Med Neerl 12:181–189, 1969
   PubMedGoogle Scholar
• Baker H, Ryan TJ: Generalized pustular psoriasis: A clinical and epidemiological study of 104 cases. Br J Dermatol 80:771–793, 1968
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Van Scott EJ: Autoradiographic analysis of turnover times of normal and psoriatic epidermis. J Invest Dermatol 45:257–262, 1965
   PubMed Web of Science ®Google Scholar
• Van Scott EJ, Ekel TM: Kinetics of hyperplasia in psoriasis. Arch Dermatol 88:373–381, 1963
   PubMedGoogle Scholar
• Voorhees JJ, Duell EA: Psoriasis as a possible de- feet of the adenyl cyclase-cyclic AMP cascade: A defective chalone mechanism? Arch Dermatol 104: 352–358; 1971
   PubMedGoogle Scholar
• Weinstein GD, Frost P: Methotrexate for psoriasis: A new therapeutic schedule. Arch Dermatol 103: 33–38, 1971
   PubMed Web of Science ®Google Scholar
• Hunter GA, Millazzo SC: Response of psoriatic arthropathy to methotrexate. Aust J Dermatol 8: 137–141, 1965
   PubMedGoogle Scholar
• Ryan TJ, Baker H: Systemic corticosteroids and folic acid antagonists in the treatment of generalized pustular psoriasis: Evaluation and prognosis based on the study of 104 cases. Br J Dermatol 81:134–145,1969
   PubMed Web of Science ®Google Scholar
• Roenigk HH Jr, Maibach HI, Weinstein GD: Use of methotrexate in psoriasis. Arch Dermatol 105: 363–365, 1972
   PubMedGoogle Scholar
• Roenigk HH Jr, Bergfeld WF, St Jacques R, et al: Hepatotoxicity of methotrexate in the treatment of psoriasis. Arch Dermatol 103:250–261, 1971
   PubMedGoogle Scholar
• Cooperative study: Psoriasis-liver-methotrexate in- teraaions. Arch Dermatol 108:36–42, 1973
   PubMedGoogle Scholar
• Dantzig PI, McEvoy B, Mauro J et al: Low dose azaribine in the treatment of psoriasis. Br J Dermatol 91:573–577, 1974
   PubMed Web of Science ®Google Scholar
• Stein KM, Shelley WB Weinberg RA: Hydroxyurea in the treatment of pustular psoriasis. Br J Dermatol 85:81–85, 1971
   PubMed Web of Science ®Google Scholar
• Peck GL, Guss SB, Key DJ: Topical lomustine in the treatment of psoriasis. Arch Dermatol 106: 172–176, 1972
   PubMedGoogle Scholar
• Tsuji T, Sugai T: Topically administered fluorouracil in psoriasis. Arch Dermatol 105:208–212, 1972
   PubMed Web of Science ®Google Scholar
• Lever WF: Pemphigus and Pemphigoid. Springfield, 111, Charles C Thomas, Publisher, 1965
   Google Scholar
• Beutner EH, Chorzelski TP, Jordan RE: Auto-sensitizacion in pemphigus and bullous pemphigoid. Springfield, 111, Charles C Thomas, Publisher, 1970
   Google Scholar
• Sams WM Jr, Jordan RE: Pemphigus antibodies: Their role in disease. J Invest Dermatol 56:474–479, 1971
   PubMed Web of Science ®Google Scholar
• Beutner EH, Jordan RE, Chorzelski TP: The immunopathology of pemphigus and bullous pemphigoid. J Invest Dermatol 51:63–80, 1968
   PubMed Web of Science ®Google Scholar
• Lever WF: Methotrexate and prednisone in pemphigus vulgaris. Arch Dermatol 106:491–497, 1972
   PubMedGoogle Scholar
• Glickman FS, Silvers SH: Pemphigus vulgaris treated with cyclophosphamide. Arch Dermatol 107: 467–468 1973
   PubMedGoogle Scholar
• Roenigk HH Jr, Deodhar S: Pemphigus treatment with azathioprine. Arch Dermatol 107:353 1973
   PubMedGoogle Scholar
• Lever WF: Pemphigoid. In Fitzpatrick TB, Arndt KA, Clark WH, et al (Editors): Dermatology in General Medicine. New York, McGraw-Hill Book Co, 1971, pp 609–614
   Google Scholar
• Krain LS, Landau JW, Newcomer VD: Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 106:657–661, 1972
   PubMed Web of Science ®Google Scholar
• Greaves M, Marks J, Burton JL: Azathioprine in treatment of bullous pemphigoid. Br Med J 1:144–145, 1971
   PubMedGoogle Scholar
• Braverman IM: Skia Signs of Systemic Disease. Philadelphia, WB Saunders Co, 1970
   Google Scholar
• Belisario JC: Cutaneous manifestations associated with internal cancer. Cutis 2:34–43; 95–103, 1966
   Google Scholar
• Metzger AL, Bohan A, Goldberg LS, et al: Polymyositis and dermatomyositis: Combined methotrexate and corticosteroid therapy. Ann Intern Med 81:182–189, 1974
   PubMed Web of Science ®Google Scholar
• Fries JF, Sharp GC, McDevitt HO, et al: Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. Arthritis Rheum 16: 154–162, 1973
   PubMed Web of Science ®Google Scholar
• Hass DC: Treatment of polymyositis with immunosuppressive drugs. Neurology 23: 55–62, 1973
   PubMed Web of Science ®Google Scholar
• Van Scott EJ, Haynes HA: Cutaneous lymphomas. In Fitzpatrick TB, Arndt KA, Clark WH, et al (Editors): Dermatology in General Medicine. New York, McGraw-Hill Book Co, 1970, pp 556–573
   Google Scholar
• Epstein EH Jr, Levin DL, Croft JD Jr: Mycosis fungoides: Survival, pronostic features, response to therapy, and autopsy findings. Medicine 51: 61–72, 1972
   PubMed Web of Science ®Google Scholar
• Edelson RL, Kirkpatrick CH, Shevach BM, et al: Preferential cutaneous infiltration by neoplastic thymus-derived lymphocytes: Morphologic and functional studies. Ann Intern Med 80: 685–692, 1974
   PubMed Web of Science ®Google Scholar
• Fuks Z, Bagshaw MA: Total-skin electron treatment of mycosis fungoides. Radiology 100: 145–150, 1971
   PubMed Web of Science ®Google Scholar
• Van Scott EJ, Winters PL: Responses of mycosis fungoides to intensive external treatment with nitrogen mustard. Arch Dermatol 102: 507–514, 1970
   PubMedGoogle Scholar
• Van Scott EJ, Auerbach R, Clendenning WE: Treatment of mycosis fungoides with cyclophosphamide. Arch Dermatol 85: 499–501, 1962
   PubMedGoogle Scholar
• Auerbach R: Mycosis fungoides successfully treated with cyclophosphamide. Arch Dermatol 101: 611, 1970
   PubMedGoogle Scholar
• Dantzig PI: Immunosuppressive and cytotoxic drugs in dermatology. Arch Dermatol 110: 393–406, 1974
   PubMedGoogle Scholar
• Haynes HA, Van Scott GJ: Therapy of mycosis fungoides. Progr Dermatol 3:1–4, 1968
   Google Scholar
• McDonald CJ, Calabresi P: Azaribine for mycosis fungoides. Arch Dermatol 103:158–167, 1971
   PubMedGoogle Scholar
• Wright JC, Golomb FM, Gumport SL: Observations on the use of cancer chemotherapeutic agents in patient with mycosis fungoides. Proc Am Assoc Cancer Res 4:73, 1963
   Google Scholar
• De Bast C, Moriame N, Wanet J, et al: Bleomycin in mycosis fungoides and reticulum cell sarcoma. Arch Dermatol 104:508–512,1971
   PubMedGoogle Scholar
• Hunter GA: Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol 87:42–45, 1972
   PubMed Web of Science ®Google Scholar
• Winkelmann RK, Kierland RR, Perry HD, et al: Management of scleroderma. Mayo Clin Proc 46: 128–134,1971
   PubMed Web of Science ®Google Scholar
• Starling KA, Donaldson MH, Haggard ME, et al: Therapy of histiocytosis X with vincristine, vinblastine and cyclophosphamide. Am J Dis Child 123:105–110, 1972
   PubMedGoogle Scholar
• Vogel CL, Templeton CJ, Templeton AC, et al: Treatment of Kaposi's sarcoma with actinomycin-D and cyclophosphamide: Results of a randomized clinical trial. Int J Cancer 8:136–143, 1971
   PubMed Web of Science ®Google Scholar